Trial Profile
A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patients to be treated with radiotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Fibroma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms RT-Immune
- 26 Jan 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 26 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 7 Aug 2023.
- 28 Mar 2022 Planned End Date changed from 30 Jul 2023 to 1 Aug 2023.